Radiosurgical devices maker Accuray posted a 30% cut in sales during its 3rd quarter, but CEO Levine says he's "encouraged" by an uptick in order volume.
Medical device maker Accuray (NSDQ:ARAY) managed to get some Wall Street love after posting a rather harsh 3rd quarter earnings report this week, with investors likely reacting to news of promising order volume growth quarter-over-quarter.
Radiosurgery devices maker Varian drops 7 points on Wall Street upon releasing its 2nd quarter financial report, in which the company reported "disappointing" results for its oncology systems revenues and uncertainty in the market in the near future.
Varian Medical Systems (NYSE:VAR) was none too pleased with the market for its oncology systems, calling its Q2 revenues for that division "disappointing, particularly in the U.S."
Medical device company Accuray explains its action to remove 2 potentially defective components of its flagship CyberKnife radiosurgery platform.
Radiosurgery devices maker Accuray (NSDQ:ARAY) released an official statement on the recall of a pair of components of its CyberKnife radiosurgery systems, warning that the devices were not manufactured to standard.
Elekta's next-generation Versa HD linear accelerator aims to provide faster and more efficient tumor targeting.
Atlanta medical device company Elekta (STO:EKTA B) this week announced FDA clearance for its Versa HD linear accelerator, allowing the company to move forward with shipping and installations.
Johnson & Johnson vows to repeal a jury decision awarding a plaintiff more than $11 million over complaints regarding transvaginal mesh implants.
MASSDEVICE ON CALL — A jury hiked up penalties against Johnson & Johnson (NYSE:JNJ) and its subsidiary Ethicon to more than $11 million after finding the companies liable in a patient injury lawsuit against the companies' transvaginal mesh implants.
California medical device maker Varian puts some skin in a Russian R&D program aimed at spurring innovation in radiotherapy technology.
Radiotherapy devices maker Varian Medical Systems (NYSE:VAR) announced a collaborative research & development initiative designed to "tap brain power" among Russia's scientific institutes.
Halt Medical wins Mexican regulatory approval for its radiofrequency-based Acessa uterine fibroid treatment.
Women's health devices maker Halt Medical touted a win from Mexican healthcare regulators who granted registration for the Acessa System for treating uterine fibroids.
The Acessa technology represents a major shift in treatment of uterine fibroids, the company has said. Fibroids are the leading global cause of hysterectomy procedures, according to the Centers for Disease Control & Prevention.